From Gene Lists to Druggable Hubs: An Integrative In Silico Framework for Alternative Lengthening of Telomeres

Between 10 and 15% of cancers maintain their telomeres without telomerase, through a recombination-based route known as alternative lengthening of telomeres (ALT). It is most common in sarcomas and gliomas. The mechanism itself is increasingly well understood, but the view from population-scale data is not: which components are perturbed most consistently across tumors, how they organize into networks, what they cost the cell metabolically, whether their expression says anything about outcome, and which existing drugs might exploit them. Here we bring together four in silico studies that used public pan-cancer data to work from gene-level alteration through networks and metabolism to clinical outcome and pharmacology, and we read them as one argument. The program is set out as five computational steps, with a sixth, experimental step that remains open. Alteration analyses of 411 telomere maintenance genes and 71 genes of ALT-associated promyelocytic leukemia (PML) bodies prioritized 20 and 13 candidates, 28 of them unique. Networks and enrichment linked those candidates to homologous recombination, break-induced replication, SUMOylation, and the DNA damage response; protein–metabolite analyses generated the untested hypothesis that nucleotide, NAD+, and methionine metabolism are engaged. A 28-gene transcriptomic score was associated with survival in sarcoma and, more weakly, in lower-grade glioma, although its discrimination was modest and, at five years in glioma, indistinguishable from chance. The five analytical steps share gene inputs and curated resources and are therefore not independent of one another. We test each step against the experimental literature and grade the evidence gene by gene. That appraisal is not uniformly favorable: TCGA carries no direct ALT status, the steps are not fully independent, the signature has never been validated externally, and the leading drug hypothesis, ATR inhibition, is contested.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-20
DOI
https://doi.org/10.3390/cancers18223713
Primary Topic
Telomeres, Telomerase, and Senescence
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

From Gene Lists to Druggable Hubs: An Integrative In Silico Framework for Alternative Lengthening of Telomeres

Isaac Armendáriz‐Castillo, Andrés López‐Cortés, Jhommara Bautista, Andrés Herrera-Yela
5 links
Cancers
Telomeres, Telomerase, and Senescence
article

From Gene Lists to Druggable Hubs: An Integrative In Silico Framework for Alternative Lengthening of Telomeres

Isaac Armendáriz‐Castillo, Andrés López‐Cortés, Jhommara Bautista, Andrés Herrera-Yela
article en

Abstract

Between 10 and 15% of cancers maintain their telomeres without telomerase, through a recombination-based route known as alternative lengthening of telomeres (ALT). It is most common in sarcomas and gliomas. The mechanism itself is increasingly well understood, but the view from population-scale data is not: which components are perturbed most consistently across tumors, how they organize into networks, what they cost the cell metabolically, whether their expression says anything about outcome, and which existing drugs might exploit them. Here we bring together four in silico studies that used public pan-cancer data to work from gene-level alteration through networks and metabolism to clinical outcome and pharmacology, and we read them as one argument. The program is set out as five computational steps, with a sixth, experimental step that remains open. Alteration analyses of 411 telomere maintenance genes and 71 genes of ALT-associated promyelocytic leukemia (PML) bodies prioritized 20 and 13 candidates, 28 of them unique. Networks and enrichment linked those candidates to homologous recombination, break-induced replication, SUMOylation, and the DNA damage response; protein–metabolite analyses generated the untested hypothesis that nucleotide, NAD+, and methionine metabolism are engaged. A 28-gene transcriptomic score was associated with survival in sarcoma and, more weakly, in lower-grade glioma, although its discrimination was modest and, at five years in glioma, indistinguishable from chance. The five analytical steps share gene inputs and curated resources and are therefore not independent of one another. We test each step against the experimental literature and grade the evidence gene by gene. That appraisal is not uniformly favorable: TCGA carries no direct ALT status, the steps are not fully independent, the signature has never been validated externally, and the leading drug hypothesis, ATR inhibition, is contested.

CancersVol. 18(22)
Universidade da Coruña (ES), Universidad de Las Américas (EC), Universidad Internacional del Ecuador (EC), Universidad Internacional SEK (EC)
Good health and well-being
Telomeres, Telomerase, and Senescence
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon